A Study of SEA-CD40 Given With Other Drugs in Cancers

Study summary

This trial is being done to see if an experimental drug (SEA-CD40) works when it's given with other cancer drugs to treat some types of cancer. It will also study side effects from the drug. There are 2 parts in this trial. In one part, participants have melanoma that has come back after treatment or can't be removed by surgery. Participants in this part will get SEA-CD40 and pembrolizumab. In the other part, participants have non-small cell lung cancer (NSCLC) that has spread through their body. These participants will get SEA-CD40, pembrolizumab, carboplatin, and pemetrexed.

Ask AI to explain this study

Start here

Key things to know

Main goalTreatment

This describes the study’s primary purpose.

What is being studiedSEA-CD40 and pembrolizumab (KEYTRUDA®)

Plus 2 other study approaches.

Who it may be forNon-small cell lung cancer (NSCLC)

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated May 11, 2025 · Source: ClinicalTrials.gov

Is enrollment open?Completed

Ask the study team to confirm whether enrollment is open.

What kind of study?Phase 2

Interventional

Where is it offered?29 U.S. locations

Locations may change over time.

Who runs it?Seagen Inc.

Study sponsor

Study overview

What this study is about

Purpose: Treatment
Study type: Interventional
Phase: Phase 2
Sponsor: Seagen Inc.
Interventions being studied: Drug: SEA-CD40; Drug: pembrolizumab (KEYTRUDA®); Drug: pemetrexed; Drug: carboplatin

Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Cancer type

Non-small cell lung cancer (NSCLC)→

Treatment approach

Immunotherapy→Chemotherapy→Surgery→

Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria

Histologically or cytologically confirmed unresectable malignancy defined as one of the following:
Cohort 1: Relapsed and/or refractory metastatic melanoma
Uveal/ocular melanoma is excluded
Must have progressed on treatment with an anti-PD-(L)1 mAb. PD-(L)1 treatment progression is defined as meeting all of the following criteria:
Has received at least 2 doses of an approved anti-PD-(L)1 mAb
Has demonstrated disease progression after PD-(L)1 as defined by RECIST v1.1.
Progressive disease has been documented within 12 weeks from the last dose of anti- PD-(L)1 mAb
Last dose of anti-PD-(L)1 must have been within 90 days prior to enrollment
Participants with a targetable BRAF mutation must have been treated with, been intolerant of, or declined treatment with BRAF/MEK targeted therapy prior to study entry
Cohort 2: Metastatic uveal melanoma
Must not have received prior treatment for advanced or metastatic disease except for prior adjuvant/neoadjuvant immunotherapy
No prior liver-directed therapy
Cohort 3: Metastatic PD-(L)1-naive melanoma
Uveal/ocular melanoma is excluded
Must not have received prior treatment for advanced or metastatic disease except for prior adjuvant/neoadjuvant immunotherapy.
For participants with a targetable BRAF mutation, prior BRAF/MEK targeted therapy is allowed if completed 4 weeks prior to first dose of study treatment.
Cohorts 4 and 5: Non-squamous NSCLC
Participants must have stage IV disease per AJCC 8th edition
No known driver mutations/alterations mutation for which targeted therapy is available
Must have non-squamous histology.
No prior therapy for metastatic disease
No prior treatment with anti-PD-(L)1 or PD-L2 agent or an antibody targeting other immuno-regulatory receptors or mechanisms
Able to provide archival tumor tissue from locations not radiated prior to biopsy. If archival tumor sample is not available a fresh baseline biopsy is required.
Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1
Measurable disease per RECIST v1.1 at baseline

Reasons someone may not be able to joinExclusion criteria

History of another malignancy within 3 years of first dose of study drug
Active central nervous system (CNS) metastases and/or carcinomatous meningitis.
Previous exposure to CD40-targeted therapy
Currently on chronic systemic steroids in excess of physiologic replacement
Has had an allogeneic tissue/solid organ transplant.
History of autoimmune disease that has required systemic treatment in the past 2 years

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

Study sites

U.S. locations

Highlands Oncology GroupSpringdale, Arkansas
The Angeles Clinic and Research InstituteLos Angeles, California
California Pacific Medical Center Research Institute/Sutter Medical CentreSan Francisco, California
University of California at San FranciscoSan Francisco, California
Florida Cancer Specialists - South RegionFort Myers, Florida
Florida Cancer Specialists - North RegionSt. Petersburg, Florida
University Cancer & Blood Center, LLCAthens, Georgia
Rush University Medical CenterChicago, Illinois
Community Health NetworkIndianapolis, Indiana
American Oncology Networks LLCBaton Rouge, Louisiana
Allina Health Cancer InstituteMinneapolis, Minnesota
University of MinnesotaMinneapolis, Minnesota

Source and freshness
Processed from ClinicalTrials.gov. Last public update: May 11, 2025. Always confirm current availability with the study team.

View original record ↗